The conventional treatment of coronary heart disease in the world is mainly metal stent, supplemented by degradable stent. In foreign countries, when the patient's condition can be treated as a degradable stent, authoritative cardiologists will give priority to it. After all, the effect of degradable stent itself in treating coronary heart disease far exceeds that of metal stent without side effects. There are two reasons why it cannot be widely promoted:
The first reason: more than half of people are not suitable for biodegradable stents and are not suitable for large-scale promotion.
The second reason: biodegradable stents are much more difficult to operate than metal stents, and not all doctors can do it.
Simply explain, the biomaterial characteristics of the fourth generation biodegradable stent are different from those of metal stents, and there are many treatment restrictions, so most types of cardiovascular blockages are not applicable. The fifth-generation biodegradable magnesium stent has been upgraded in materials, and the range of indications for treatment has been expanded, but it is still not suitable for all cases of blood vessel blockage, so it is impossible for biodegradable magnesium stent to completely replace metal stent in a short time, which is by no means the so-called immature technology.
At the same time, due to the special physical characteristics of the material and the need for doctors to accurately grasp the patient's condition, the overall operation difficulty has been improved a lot in the treatment of metal stents. Not every doctor who can do metal stents can do degradable stent surgery. This is why every patient who wants to do biodegradable stent needs to evaluate his condition in detail. The fifth generation magnesium alloy stent has achieved good results in many clinical trials of cardiovascular diseases. The fifth generation magnesium alloy stent has been introduced into clinical application in hospitals in Hong Kong, and accumulated rich clinical treatment experience, which has brought therapeutic gospel to patients with cardiovascular diseases in mainland China.